RxDoctor Payments Data

James Seely, MD

Family Medicine · New Haven, CTNPI 1629065008

Payments from drug & device makers

$2,794in general payments, 2019–2025

Across 34 payments — averaging $82.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$512
  • Lilly USA, LLC$459
  • Sanofi-aventis U.S. LLC$373
  • Otsuka America Pharmaceutical, Inc.$249
  • Bayer$125
  • Amgen$125
  • plus $951 from 11 others

What the payments were for

  • Food & beverage$2,74498%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,794 in reported general payments places this provider in the 80th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$16,091
Medicare patients
281
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$102,810
TrulicityDulaglutide64$66,222
OzempicSemaglutide27$48,319
JanuviaSitagliptin Phosphate42$47,540
OxycontinOxycodone Hcl14$20,468
EliquisApixaban23$17,080
MounjaroTirzepatide16$16,941
MyrbetriqMirabegron20$16,717
XareltoRivaroxaban15$15,938
EntrestoSacubitril/Valsartan14$14,265
FarxigaDapagliflozin Propanediol11$10,981
LinzessLinaclotide14$9,853
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$6,577
Spiriva HandihalerTiotropium Bromide12$6,037
Lidocaine45$6,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$512$102,81087 claims
Lilly USA, LLCTrulicity, Mounjaro$459$83,16380 claims
Novo NordiskOzempic$90$48,31927 claims
Johnson & JohnsonXarelto$94$15,93815 claims
AstraZenecaFarxiga$125$10,98111 claims
GSKShingrix$125$3,74921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 family medicine providers in Connecticut.

Other family medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →